Page last updated: 2024-10-30

metformin and Brain Neoplasms

metformin has been researched along with Brain Neoplasms in 42 studies

Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.

Brain Neoplasms: Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.

Research Excerpts

ExcerptRelevanceReference
"Memantine, mefloquine, and metformin can be combined safely with TMZ in patients with newly diagnosed glioblastoma."9.30Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma. ( Aldape, KD; Alfred Yung, WK; Conrad, CA; de Groot, JF; Gilbert, MR; Groves, MD; Hess, KR; Loghin, ME; Mammoser, AG; Maraka, S; Melguizo-Gavilanes, I; O'Brien, BJ; Penas-Prado, M; Puduvalli, VK; Sulman, EP; Tremont-Lukats, IW, 2019)
"New treatments are needed to improve the overall survival of patients with glioblastoma Metformin is known for anti-tumorigenic effects in cancers, including breast and pancreas cancers."8.31Metformin use is associated with longer survival in glioblastoma patients with MGMT gene silencing. ( Al-Saadi, T; Diaz, RJ; Jatana, S; Khalaf, R; Mohammad, AH; Ruiz-Barerra, MA, 2023)
"To investigate the effects of metformin, dichloroacetate (DCA), and memantine on T98G and U87-MG human glioblastoma (GBM) cells to target tumor cell metabolism in a multi-directional manner."8.02Targeting Cancer Cell Metabolism with Metformin, Dichloroacetate and Memantine in Glioblastoma (GBM). ( Albayrak, G; Dere, UA; Emmez, H; Konac, E, 2021)
"The purpose of the study is to investigate the efficacy of combined treatment with temozolomide (TMZ) and metformin for glioblastoma (GBM) in vitro and in vivo."7.88High-Dose Metformin Plus Temozolomide Shows Increased Anti-tumor Effects in Glioblastoma In Vitro and In Vivo Compared with Monotherapy. ( Hong, YK; Lee, JE; Lim, JH; Yang, SH, 2018)
"It has been reported that metformin acts synergistically with temozolomide (TMZ) to inhibit proliferation of glioma cells including glioblastoma multiforme (GBM)."7.83Metformin treatment reduces temozolomide resistance of glioblastoma cells. ( Kim, DH; Li, S; Liu, Y; Lu, G; Xue, H; Yang, SH; Zhu, JJ, 2016)
"High-grade gliomas, glioblastomas (GB), are refractory to conventional treatment combining surgery, chemotherapy, mainly temozolomide, and radiotherapy."7.81Metformin inhibits growth of human glioblastoma cells and enhances therapeutic response. ( Brem, H; Cohen-Jonathan Moyal, E; Dahan, P; Dang, VT; Lemarié, A; Saland, E; Sarry, JE; Scotland, SJ; Sesen, J; Skuli, N; Toulas, C; Tyler, BM, 2015)
" Interestingly, our findings showed an association of metformin therapy and prolonged progression-free survival in glioblastoma patients with diabetes and therefore serve as a foundation for further preclinical and clinical investigations."7.81Metformin influences progression in diabetic glioblastoma patients. ( Adeberg, S; Ben Harrabi, S; Bernhardt, D; Bostel, T; Debus, J; Diehl, C; Koelsche, C; Mohr, A; Rieken, S, 2015)
"Glioblastoma is the most frequent and lethal primary central nervous system tumor in adults, accounting for around 15% of intracranial neoplasms and 40-50% of all primary malignant brain tumors, with an annual incidence of 3-6 cases per 100,000 population."5.72Exploring the Mechanism of Adjuvant Treatment of Glioblastoma Using Temozolomide and Metformin. ( Chang, PC; Chen, HY; Feng, SW; Huang, SM; Hueng, DY; Li, YF, 2022)
"Glioma is the most common type of brain cancer."5.62Combination of metformin and cold atmospheric plasma induces glioma cell death to associate with c-Fos. ( Ahmad, N; Meng, X; Sun, M; Yang, F; Yang, J; Yu, H; Zhao, R; Zhou, Y; Zhu, C; Zhuang, J, 2021)
"Metformin has been linked to improve survival of patients with various cancers."5.56Use of metformin and outcome of patients with newly diagnosed glioblastoma: Pooled analysis. ( Chinot, O; Genbrugge, E; Gorlia, T; Hau, P; Nabors, B; Seliger, C; Stupp, R; Weller, M, 2020)
"Memantine, mefloquine, and metformin can be combined safely with TMZ in patients with newly diagnosed glioblastoma."5.30Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma. ( Aldape, KD; Alfred Yung, WK; Conrad, CA; de Groot, JF; Gilbert, MR; Groves, MD; Hess, KR; Loghin, ME; Mammoser, AG; Maraka, S; Melguizo-Gavilanes, I; O'Brien, BJ; Penas-Prado, M; Puduvalli, VK; Sulman, EP; Tremont-Lukats, IW, 2019)
"New treatments are needed to improve the overall survival of patients with glioblastoma Metformin is known for anti-tumorigenic effects in cancers, including breast and pancreas cancers."4.31Metformin use is associated with longer survival in glioblastoma patients with MGMT gene silencing. ( Al-Saadi, T; Diaz, RJ; Jatana, S; Khalaf, R; Mohammad, AH; Ruiz-Barerra, MA, 2023)
"To investigate the effects of metformin, dichloroacetate (DCA), and memantine on T98G and U87-MG human glioblastoma (GBM) cells to target tumor cell metabolism in a multi-directional manner."4.02Targeting Cancer Cell Metabolism with Metformin, Dichloroacetate and Memantine in Glioblastoma (GBM). ( Albayrak, G; Dere, UA; Emmez, H; Konac, E, 2021)
"The purpose of the study is to investigate the efficacy of combined treatment with temozolomide (TMZ) and metformin for glioblastoma (GBM) in vitro and in vivo."3.88High-Dose Metformin Plus Temozolomide Shows Increased Anti-tumor Effects in Glioblastoma In Vitro and In Vivo Compared with Monotherapy. ( Hong, YK; Lee, JE; Lim, JH; Yang, SH, 2018)
"It has been reported that metformin acts synergistically with temozolomide (TMZ) to inhibit proliferation of glioma cells including glioblastoma multiforme (GBM)."3.83Metformin treatment reduces temozolomide resistance of glioblastoma cells. ( Kim, DH; Li, S; Liu, Y; Lu, G; Xue, H; Yang, SH; Zhu, JJ, 2016)
"High-grade gliomas, glioblastomas (GB), are refractory to conventional treatment combining surgery, chemotherapy, mainly temozolomide, and radiotherapy."3.81Metformin inhibits growth of human glioblastoma cells and enhances therapeutic response. ( Brem, H; Cohen-Jonathan Moyal, E; Dahan, P; Dang, VT; Lemarié, A; Saland, E; Sarry, JE; Scotland, SJ; Sesen, J; Skuli, N; Toulas, C; Tyler, BM, 2015)
" Interestingly, our findings showed an association of metformin therapy and prolonged progression-free survival in glioblastoma patients with diabetes and therefore serve as a foundation for further preclinical and clinical investigations."3.81Metformin influences progression in diabetic glioblastoma patients. ( Adeberg, S; Ben Harrabi, S; Bernhardt, D; Bostel, T; Debus, J; Diehl, C; Koelsche, C; Mohr, A; Rieken, S, 2015)
"Metformin has in-vitro anti-cancer activity, through AMPK activation and mTOR inhibition."3.01A Phase I clinical trial of dose-escalated metabolic therapy combined with concomitant radiation therapy in high-grade glioma. ( Amit, U; Anikster, Y; Champ, CE; Cohen, ZR; Furman, O; Genssin, H; Hemi, R; Jan, E; Kanety, H; Lawrence, YR; Mardor, Y; Pechthold, RG; Plotkin, L; Porper, K; Shimoni-Sebag, A; Shpatz, Y; Symon, Z; Talianski, A; Zach, L, 2021)
"Metformin is an antidiabetic drug currently under investigation as a potential antineoplastic agent."1.91Heterogeneity of Amino Acid Profiles of Proneural and Mesenchymal Brain-Tumor Initiating Cells. ( Ammer, LM; Dettmer, K; Hau, P; Heckscher, S; Jachnik, B; Leidgens, V; Moeckel, S; Oefner, PJ; Proescholdt, M; Rauer, L; Riemenschneider, MJ; Seliger, C; Vollmann-Zwerenz, A; Wüster, AL, 2023)
"Glioblastoma is the most frequent and lethal primary central nervous system tumor in adults, accounting for around 15% of intracranial neoplasms and 40-50% of all primary malignant brain tumors, with an annual incidence of 3-6 cases per 100,000 population."1.72Exploring the Mechanism of Adjuvant Treatment of Glioblastoma Using Temozolomide and Metformin. ( Chang, PC; Chen, HY; Feng, SW; Huang, SM; Hueng, DY; Li, YF, 2022)
"Glioma is the most common type of brain cancer."1.62Combination of metformin and cold atmospheric plasma induces glioma cell death to associate with c-Fos. ( Ahmad, N; Meng, X; Sun, M; Yang, F; Yang, J; Yu, H; Zhao, R; Zhou, Y; Zhu, C; Zhuang, J, 2021)
"Patients with new-onset type 2 diabetes mellitus diagnosed from 1999 to 2005 in the nationwide database of Taiwan's national health insurance were used to enroll study subjects."1.62Metformin and Risk of Malignant Brain Tumors in Patients with Type 2 Diabetes Mellitus. ( Tseng, CH, 2021)
"Radiation is a current standard treatment of glioma."1.56Inhibition of mitochondria NADH-Ubiquinone oxidoreductase (complex I) sensitizes the radioresistant glioma U87MG cells to radiation. ( Dong, H; Feng, B; Gao, C; Gao, X; Mao, W; Sun, C; Wang, J; Wang, Y; Yang, Y; Zhang, B; Zhang, H; Zhang, J; Zhang, L, 2020)
"Metformin has been linked to improve survival of patients with various cancers."1.56Use of metformin and outcome of patients with newly diagnosed glioblastoma: Pooled analysis. ( Chinot, O; Genbrugge, E; Gorlia, T; Hau, P; Nabors, B; Seliger, C; Stupp, R; Weller, M, 2020)
"Treatment with metformin reduced STAT3-phosphorylation in all investigated BTICs and TCs."1.46Stattic and metformin inhibit brain tumor initiating cells by reducing STAT3-phosphorylation. ( Bogdahn, U; Hau, P; Leidgens, V; Moeckel, S; Proescholdt, M; Proske, J; Rauer, L; Renner, K; Riemenschneider, MJ; Seliger, C; Vollmann-Zwerenz, A, 2017)
"Metformin treatment may be useful for modulating the metastatic capacity by reducing VEGF expression and blocking epithelial-to-mesenchymal transition."1.42Clinicopathological significance of N-cadherin and VEGF in advanced gastric cancer brain metastasis and the effects of metformin in preclinical models. ( Chin, HM; Choi, HJ; Jun, KH; Jung, JH; Kim, SH; Kim, YI; Lee, JE; Yang, SH, 2015)
"Metformin or olanzapine have been shown independently to enhance AMPK activation."1.37Can the therapeutic effects of temozolomide be potentiated by stimulating AMP-activated protein kinase with olanzepine and metformin? ( Halatsch, ME; Karpel-Massler, G; Kast, RE, 2011)

Research

Studies (42)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's24 (57.14)24.3611
2020's18 (42.86)2.80

Authors

AuthorsStudies
Tseng, CH2
Sanati, M1
Aminyavari, S1
Mollazadeh, H1
Motamed-Sanaye, A1
Bibak, B1
Mohtashami, E1
Teng, Y1
Afshari, AR1
Sahebkar, A2
Feng, SW1
Chang, PC1
Chen, HY1
Hueng, DY1
Li, YF1
Huang, SM1
Zhu, L1
Liu, J1
Qiu, M1
Chen, J2
Liang, Q1
Peng, G1
Zou, Z1
Seliger, C7
Meyer, AL1
Leidgens, V3
Rauer, L3
Moeckel, S3
Jachnik, B3
Proske, J2
Dettmer, K3
Rothhammer-Hampl, T1
Kaulen, LD1
Riemenschneider, MJ5
Oefner, PJ2
Kreutz, M2
Schmidt, NO1
Merrill, M1
Uhl, M1
Renner, K3
Vollmann-Zwerenz, A4
Proescholdt, M5
Hau, P7
Wüster, AL1
Ammer, LM1
Heckscher, S1
Mohammad, AH1
Jatana, S1
Ruiz-Barerra, MA1
Khalaf, R1
Al-Saadi, T1
Diaz, RJ1
Cole, AJ1
Fayomi, AP1
Anyaeche, VI1
Bai, S1
Buckanovich, RJ1
Ayoub, R1
Ruddy, RM1
Cox, E1
Oyefiade, A1
Derkach, D1
Laughlin, S1
Ades-Aron, B1
Shirzadi, Z1
Fieremans, E1
MacIntosh, BJ1
de Medeiros, CB1
Skocic, J1
Bouffet, E1
Miller, FD1
Morshead, CM1
Mabbott, DJ1
Gibson, EM1
Monje, M1
Gao, X1
Yang, Y2
Wang, J5
Zhang, L3
Sun, C1
Wang, Y3
Zhang, J4
Dong, H1
Zhang, H2
Gao, C2
Zhang, B1
Feng, B1
Mao, W1
Nguépy Keubo, FR1
Mboua, PC1
Djifack Tadongfack, T1
Fokouong Tchoffo, E1
Tasson Tatang, C1
Ide Zeuna, J1
Noupoue, EM1
Tsoplifack, CB1
Folefack, GO1
Kettani, M1
Bandelier, P1
Huo, J1
Li, H4
Yu, D1
Arulsamy, N1
AlAbbad, S1
Sardot, T1
Lekashvili, O1
Decato, D1
Lelj, F1
Alexander Ross, JB1
Rosenberg, E1
Nazir, H1
Muthuswamy, N1
Louis, C1
Jose, S1
Prakash, J1
Buan, MEM1
Flox, C1
Chavan, S1
Shi, X1
Kauranen, P1
Kallio, T1
Maia, G1
Tammeveski, K1
Lymperopoulos, N1
Carcadea, E1
Veziroglu, E1
Iranzo, A1
M Kannan, A1
Arunamata, A1
Tacy, TA1
Kache, S1
Mainwaring, RD1
Ma, M1
Maeda, K1
Punn, R1
Noguchi, S1
Hahn, S3
Iwasa, Y3
Ling, J2
Voccio, JP2
Kim, Y3
Song, J3
Bascuñán, J2
Chu, Y1
Tomita, M1
Cazorla, M1
Herrera, E1
Palomeque, E1
Saud, N1
Hoplock, LB1
Lobchuk, MM1
Lemoine, J1
Li, X10
Henson, MA1
Unsihuay, D1
Qiu, J1
Swaroop, S1
Nagornov, KO1
Kozhinov, AN1
Tsybin, YO1
Kuang, S1
Laskin, J1
Zin, NNINM1
Mohamad, MN1
Roslan, K1
Abdul Wafi, S1
Abdul Moin, NI1
Alias, A1
Zakaria, Y1
Abu-Bakar, N1
Naveed, A1
Jilani, K1
Siddique, AB1
Akbar, M1
Riaz, M1
Mushtaq, Z1
Sikandar, M1
Ilyas, S1
Bibi, I1
Asghar, A1
Rasool, G1
Irfan, M1
Li, XY1
Zhao, S1
Fan, XH1
Chen, KP1
Hua, W1
Liu, ZM1
Xue, XD1
Zhou, B1
Zhang, S2
Xing, YL1
Chen, MA1
Sun, Y2
Neradilek, MB1
Wu, XT1
Zhang, D2
Huang, W1
Cui, Y1
Yang, QQ1
Li, HW1
Zhao, XQ1
Hossein Rashidi, B1
Tarafdari, A1
Ghazimirsaeed, ST1
Shahrokh Tehraninezhad, E1
Keikha, F1
Eslami, B1
Ghazimirsaeed, SM1
Jafarabadi, M1
Silvani, Y1
Lovita, AND1
Maharani, A1
Wiyasa, IWA1
Sujuti, H1
Ratnawati, R1
Raras, TYM1
Lemin, AS1
Rahman, MM1
Pangarah, CA1
Kiyu, A1
Zeng, C2
Du, H1
Lin, D1
Jalan, D1
Rubagumya, F1
Hopman, WM1
Vanderpuye, V1
Lopes, G1
Seruga, B1
Booth, CM1
Berry, S1
Hammad, N1
Sajo, EA1
Okunade, KS1
Olorunfemi, G1
Rabiu, KA1
Anorlu, RI1
Xu, C2
Xiang, Y1
Xu, X1
Zhou, L2
Dong, X1
Tang, S1
Gao, XC1
Wei, CH1
Zhang, RG1
Cai, Q1
He, Y1
Tong, F1
Dong, JH1
Wu, G1
Dong, XR1
Tang, X1
Tao, F1
Xiang, W1
Zhao, Y2
Jin, L1
Tao, H1
Lei, Y1
Gan, H1
Huang, Y1
Chen, Y4
Chen, L3
Shan, A1
Zhao, H2
Wu, M2
Ma, Q1
Zhang, E1
Li, Y6
Xue, F1
Deng, L1
Liu, L2
Yan, Z2
Meng, J1
Chen, G2
Anastassiadou, M1
Bernasconi, G1
Brancato, A1
Carrasco Cabrera, L1
Greco, L1
Jarrah, S1
Kazocina, A1
Leuschner, R1
Magrans, JO1
Miron, I1
Nave, S1
Pedersen, R1
Reich, H1
Rojas, A1
Sacchi, A1
Santos, M1
Theobald, A1
Vagenende, B1
Verani, A1
Du, L1
Liu, X2
Ren, Y1
Li, J7
Li, P1
Jiao, Q1
Meng, P1
Wang, F2
Wang, YS1
Wang, C3
Zhou, X3
Wang, W1
Wang, S2
Hou, J1
Zhang, A1
Lv, B1
Pang, D1
Lu, K1
Ahmad, NH1
Wang, L1
Zhu, J2
Zhuang, T1
Tu, J1
Zhao, Z1
Qu, Y1
Yao, H1
Wang, X5
Lee, DF1
Shen, J3
Wen, L1
Huang, G2
Xie, X1
Zhao, Q1
Hu, W1
Zhang, Y4
Wu, X1
Lu, J2
Li, M1
Li, W2
Wu, W1
Du, F1
Ji, H1
Yang, X2
Xu, Z1
Wan, L1
Wen, Q1
Cho, CH1
Zou, C1
Xiao, Z1
Liao, J1
Su, X1
Bi, Z1
Su, Q1
Huang, H1
Wei, Y2
Gao, Y2
Na, KJ1
Choi, H1
Oh, HR1
Kim, YH1
Lee, SB1
Jung, YJ1
Koh, J1
Park, S1
Lee, HJ1
Jeon, YK1
Chung, DH1
Paeng, JC1
Park, IK1
Kang, CH1
Cheon, GJ1
Kang, KW1
Lee, DS1
Kim, YT1
Pajuelo-Lozano, N1
Alcalá, S1
Sainz, B1
Perona, R1
Sanchez-Perez, I1
Logotheti, S1
Marquardt, S1
Gupta, SK1
Richter, C1
Edelhäuser, BAH1
Engelmann, D1
Brenmoehl, J1
Söhnchen, C1
Murr, N1
Alpers, M1
Singh, KP1
Wolkenhauer, O1
Heckl, D1
Spitschak, A1
Pützer, BM1
Liao, Y1
Cheng, J1
Kong, X1
Li, S2
Zhang, M4
Yang, T2
Dong, Y1
Xu, Y1
Yuan, Z1
Cao, J1
Zheng, Y1
Luo, Z1
Mei, Z1
Yao, Y1
Liu, Z2
Liang, C1
Yang, H1
Song, Y1
Yu, K1
Zhu, C2
Huang, Z1
Qian, J1
Ge, J1
Hu, J2
Wang, H2
Liu, Y5
Mi, Y1
Kong, H1
Xi, D1
Yan, W1
Luo, X1
Ning, Q1
Chang, X2
Zhang, T2
Wang, Q2
Rathore, MG1
Reddy, K1
Chen, H1
Shin, SH1
Ma, WY1
Bode, AM1
Dong, Z1
Mu, W1
Liu, C3
Gao, F1
Qi, Y1
Lu, H1
Zhang, X4
Cai, X1
Ji, RY1
Hou, Y3
Tian, J2
Shi, Y1
Ying, S1
Tan, M1
Feng, G1
Kuang, Y1
Chen, D1
Wu, D3
Zhu, ZQ1
Tang, HX1
Shi, ZE1
Kang, J1
Liu, Q1
Qi, J2
Mu, J1
Cong, Z1
Chen, S2
Fu, D1
Li, Z2
Celestrin, CP1
Rocha, GZ1
Stein, AM1
Guadagnini, D1
Tadelle, RM1
Saad, MJA1
Oliveira, AG1
Bianconi, V1
Bronzo, P1
Banach, M1
Mannarino, MR1
Pirro, M1
Patsourakos, NG1
Kouvari, M1
Kotidis, A1
Kalantzi, KI1
Tsoumani, ME1
Anastasiadis, F1
Andronikos, P1
Aslanidou, T1
Efraimidis, P1
Georgiopoulos, A1
Gerakiou, K1
Grigoriadou-Skouta, E1
Grigoropoulos, P1
Hatzopoulos, D1
Kartalis, A1
Lyras, A1
Markatos, G1
Mikrogeorgiou, A1
Myroforou, I1
Orkopoulos, A1
Pavlidis, P1
Petras, C1
Riga, M1
Skouloudi, M1
Smyrnioudis, N1
Thomaidis, K1
Tsikouri, GE1
Tsikouris, EI1
Zisimos, K1
Vavoulis, P1
Vitali, MG1
Vitsas, G1
Vogiatzidis, C1
Chantanis, S1
Fousas, S1
Panagiotakos, DB1
Tselepis, AD1
Jungen, C1
Alken, FA1
Eickholt, C1
Scherschel, K1
Kuklik, P1
Klatt, N1
Schwarzl, J1
Moser, J1
Jularic, M1
Akbulak, RO1
Schaeffer, B1
Willems, S1
Meyer, C1
Nowak, JK1
Szczepanik, M1
Trypuć, M1
Pogorzelski, A1
Bobkowski, W1
Grytczuk, M1
Minarowska, A1
Wójciak, R1
Walkowiak, J1
Lu, Y1
Xi, J1
Li, C2
Chen, W2
Hu, X1
Zhang, F1
Wei, H1
Wang, Z1
Gurzu, S1
Jung, I1
Sugimura, H2
Stefan-van Staden, RI1
Yamada, H1
Natsume, H1
Iwashita, Y1
Szodorai, R1
Szederjesi, J1
Yari, D1
Ehsanbakhsh, Z1
Validad, MH1
Langroudi, FH1
Esfandiari, H1
Prager, A1
Hassanpour, K1
Kurup, SP1
Mets-Halgrimson, R1
Yoon, H1
Zeid, JL1
Mets, MB1
Rahmani, B1
Araujo-Castillo, RV1
Culquichicón, C1
Solis Condor, R1
Efendi, F1
Sebayang, SK1
Astutik, E1
Hadisuyatmana, S1
Has, EMM1
Kuswanto, H1
Foroutan, T1
Ahmadi, F1
Moayer, F1
Khalvati, S1
Zhang, Q2
Lyu, Y1
Huang, J1
Yu, N1
Wen, Z1
Hou, H1
Zhao, T1
Gupta, A1
Khosla, N1
Govindasamy, V1
Saini, A1
Annapurna, K1
Dhakate, SR1
Akkaya, Ö1
Chandgude, AL1
Dömling, A1
Harnett, J1
Oakes, K1
Carè, J1
Leach, M1
Brown, D1
Cramer, H1
Pinder, TA1
Steel, A1
Anheyer, D1
Cantu, J1
Valle, J1
Flores, K1
Gonzalez, D1
Valdes, C1
Lopez, J1
Padilla, V1
Alcoutlabi, M1
Parsons, J1
Núñez, K1
Hamed, M1
Fort, D1
Bruce, D1
Thevenot, P1
Cohen, A1
Weber, P1
Menezes, AMB1
Gonçalves, H1
Perez-Padilla, R1
Jarvis, D1
de Oliveira, PD1
Wehrmeister, FC1
Mir, S1
Wong, J1
Ryan, CM1
Bellingham, G1
Singh, M2
Waseem, R1
Eckert, DJ1
Chung, F1
Hegde, H1
Shimpi, N1
Panny, A1
Glurich, I1
Christie, P1
Acharya, A1
English, KL1
Downs, M1
Goetchius, E1
Buxton, R1
Ryder, JW1
Ploutz-Snyder, R1
Guilliams, M1
Scott, JM1
Ploutz-Snyder, LL1
Martens, C1
Goplen, FK1
Aasen, T1
Gjestad, R1
Nordfalk, KF1
Nordahl, SHG1
Inoue, T1
Soshi, S1
Kubota, M1
Marumo, K1
Mortensen, NP1
Caffaro, MM1
Patel, PR2
Uddin, MJ1
Aravamudhan, S1
Sumner, SJ1
Fennell, TR1
Gal, RL1
Cohen, NJ1
Kruger, D1
Beck, RW1
Bergenstal, RM1
Calhoun, P1
Cushman, T1
Haban, A1
Hood, K1
Johnson, ML1
McArthur, T1
Olson, BA1
Weinstock, RS1
Oser, SM1
Oser, TK1
Bugielski, B1
Strayer, H1
Aleppo, G1
Maruyama, H1
Hirayama, K1
Yamashita, M1
Ohgi, K1
Tsujimoto, R1
Takayasu, M1
Shimohata, H1
Kobayashi, M1
Buscagan, TM1
Rees, DC1
Jaborek, JR1
Zerby, HN1
Wick, MP1
Fluharty, FL1
Moeller, SJ1
Razavi, P1
Dickler, MN1
Shah, PD1
Toy, W1
Brown, DN1
Won, HH1
Li, BT1
Shen, R1
Vasan, N1
Modi, S1
Jhaveri, K1
Caravella, BA1
Patil, S1
Selenica, P1
Zamora, S1
Cowan, AM1
Comen, E1
Singh, A1
Covey, A1
Berger, MF1
Hudis, CA1
Norton, L1
Nagy, RJ1
Odegaard, JI1
Lanman, RB1
Solit, DB1
Robson, ME1
Lacouture, ME1
Brogi, E1
Reis-Filho, JS1
Moynahan, ME1
Scaltriti, M1
Chandarlapaty, S1
Papouskova, K1
Moravcova, M1
Masrati, G1
Ben-Tal, N1
Sychrova, H1
Zimmermannova, O1
Fang, J1
Fan, Y1
Luo, T2
Su, H1
Tsetseris, L1
Anthopoulos, TD1
Liu, SF1
Zhao, K1
Sacan, O1
Turkyilmaz, IB1
Bayrak, BB1
Mutlu, O1
Akev, N1
Yanardag, R1
Gruber, S1
Kamnoedboon, P1
Özcan, M1
Srinivasan, M1
Jo, YH1
Oh, HK1
Jeong, SY1
Lee, BG1
Zheng, J1
Guan, H1
Li, D2
Tan, H1
Maji, TK1
J R, A1
Mukherjee, S1
Alexander, R1
Mondal, A1
Das, S1
Sharma, RK1
Chakraborty, NK1
Dasgupta, K1
Sharma, AMR1
Hawaldar, R1
Pandey, M1
Naik, A1
Majumdar, K1
Pal, SK1
Adarsh, KV1
Ray, SK1
Karmakar, D1
Ma, Y2
Gao, W1
Ma, S1
Lin, W1
Zhou, T1
Wu, T1
Wu, Q1
Ye, C1
He, X1
Jiang, F1
Yuan, D1
Chen, Q1
Hong, M1
Chen, K1
Hussain, M1
Razi, SS1
Yildiz, EA1
Zhao, J1
Yaglioglu, HG1
Donato, MD1
Jiang, J1
Jamil, MI1
Zhan, X1
Chen, F1
Cheng, D1
Wu, CT1
Utsunomiya, T1
Ichii, T1
Fujinami, S1
Nakajima, K1
Sanchez, DM1
Raucci, U1
Ferreras, KN1
Martínez, TJ1
Mordi, NA1
Mordi, IR1
Singh, JS1
McCrimmon, RJ1
Struthers, AD1
Lang, CC1
Wang, XW1
Yuan, LJ1
Chen, WF1
Luo, R1
Yang, K1
Amarasiri, SS1
Attanayake, AP1
Arawwawala, LDAM1
Jayatilaka, KAPW1
Mudduwa, LKB1
Ogunsuyi, O2
Akanni, O1
Alabi, O1
Alimba, C1
Adaramoye, O1
Cambier, S1
Eswara, S1
Gutleb, AC1
Bakare, A1
Gu, Z1
Cong, J1
Pellegrini, M1
Palmieri, S1
Ricci, A1
Serio, A1
Paparella, A1
Lo Sterzo, C1
Jadeja, SD1
Vaishnav, J1
Mansuri, MS1
Shah, C1
Mayatra, JM1
Shah, A1
Begum, R1
Song, H2
Lian, Y1
Wan, T1
Schultz-Lebahn, A1
Skipper, MT1
Hvas, AM1
Larsen, OH1
Hijazi, Z1
Granger, CB1
Hohnloser, SH1
Westerbergh, J1
Lindbäck, J1
Alexander, JH1
Keltai, M1
Parkhomenko, A1
López-Sendón, JL1
Lopes, RD1
Siegbahn, A1
Wallentin, L1
El-Tarabany, MS1
Saleh, AA1
El-Araby, IE1
El-Magd, MA1
van Ginkel, MPH1
Schijven, MP1
van Grevenstein, WMU1
Schreuder, HWR1
Pereira, EDM1
da Silva, J1
Carvalho, PDS1
Grivicich, I1
Picada, JN1
Salgado Júnior, IB1
Vasques, GJ1
Pereira, MADS1
Reginatto, FH1
Ferraz, ABF1
Vasilenko, EA1
Gorshkova, EN1
Astrakhantseva, IV1
Drutskaya, MS1
Tillib, SV1
Nedospasov, SA1
Mokhonov, VV1
Nam, YW1
Cui, M1
Orfali, R1
Viegas, A1
Nguyen, M1
Mohammed, EHM1
Zoghebi, KA1
Rahighi, S1
Parang, K1
Patterson, KC1
Kahanovitch, U1
Gonçalves, CM1
Hablitz, JJ1
Staruschenko, A1
Mulkey, DK1
Olsen, ML1
Gu, L1
Cao, X1
Mukhtar, A1
Wu, K1
Zhang, YY1
Zhu, Y1
Lu, DZ1
Dong, W1
Bi, WJ1
Feng, XJ1
Wen, LM1
Sun, H1
Qi, MC1
Chang, CC1
Dinh, TK1
Lee, YA1
Wang, FN1
Sung, YC1
Yu, PL1
Chiu, SC1
Shih, YC1
Wu, CY1
Huang, YD1
Lu, TT1
Wan, D1
Sakizadeh, J1
Cline, JP1
Snyder, MA1
Kiely, CJ1
McIntosh, S1
Jiang, X1
Cao, JW1
Zhao, CK1
Yang, R1
Zhang, QY1
Chen, KJ2
Liu, H1
He, Z1
Chen, B1
Wu, J1
Du, X1
Moore, J1
Blank, BR1
Eksterowicz, J1
Sutimantanapi, D1
Yuen, N1
Metzger, T1
Chan, B1
Huang, T1
Chen, X1
Duong, F1
Kong, W1
Chang, JH2
Sun, J1
Zavorotinskaya, T1
Ye, Q1
Junttila, MR1
Ndubaku, C1
Friedman, LS1
Fantin, VR1
Sun, D1
Fei, P1
Xie, Q1
Jiang, Y1
Feng, H1
Chang, Y1
Kang, H1
Xing, M1
Shao, Z1
Yuan, C1
Wu, Y1
Allan, R1
Canham, K1
Wallace, R1
Singh, D1
Ward, J1
Cooper, A1
Newcomb, C1
Nammour, S1
El Mobadder, M1
Maalouf, E1
Namour, M1
Namour, A1
Rey, G1
Matamba, P1
Matys, J1
Zeinoun, T1
Grzech-Leśniak, K1
Segabinazi Peserico, C1
Garozi, L1
Zagatto, AM1
Machado, FA1
Hirth, JM1
Dinehart, EE1
Lin, YL1
Kuo, YF1
Nouri, SS1
Ritchie, C1
Volow, A1
Li, B2
McSpadden, S1
Dearman, K1
Kotwal, A1
Sudore, RL1
Ward, L1
Thakur, A1
Kondadasula, SV1
Ji, K1
Schalk, DL1
Bliemeister, E1
Ung, J1
Aboukameel, A1
Casarez, E1
Sloane, BF1
Lum, LG1
Xiao, M1
Feng, X1
Gao, R1
Du, B1
Brooks, T1
Zwirner, J1
Hammer, N1
Ondruschka, B1
Jermy, M1
Luengo, A1
Marzo, I1
Reback, M1
Daubit, IM1
Fernández-Moreira, V1
Metzler-Nolte, N1
Gimeno, MC1
Tonchev, I1
Heberman, D1
Peretz, A1
Medvedovsky, AT1
Gotsman, I1
Rashi, Y1
Poles, L1
Goland, S1
Perlman, GY1
Danenberg, HD1
Beeri, R1
Shuvy, M1
Fu, Q1
Yang, D1
Sarapulova, A1
Pang, Q1
Meng, Y1
Wei, L1
Ehrenberg, H1
Kim, CC1
Jeong, SH1
Oh, KH1
Nam, KT1
Sun, JY1
Ning, J1
Duan, Z1
Kershaw, SV1
Rogach, AL1
Gao, Z1
Wang, T1
Li, Q1
Cao, T1
Guo, L1
Fu, Y1
Seeger, ZL1
Izgorodina, EI1
Hue, S1
Beldi-Ferchiou, A1
Bendib, I1
Surenaud, M1
Fourati, S1
Frapard, T1
Rivoal, S1
Razazi, K1
Carteaux, G1
Delfau-Larue, MH1
Mekontso-Dessap, A1
Audureau, E1
de Prost, N1
Gao, SS1
Duangthip, D1
Lo, ECM1
Chu, CH1
Roberts, W1
Rosenheck, RA1
Miyake, T1
Kimoto, E1
Luo, L1
Mathialagan, S1
Horlbogen, LM1
Ramanathan, R1
Wood, LS1
Johnson, JG1
Le, VH1
Vourvahis, M1
Rodrigues, AD1
Muto, C1
Furihata, K1
Sugiyama, Y1
Kusuhara, H1
Gong, Q1
Song, W1
Sun, B1
Cao, P1
Gu, S1
Sun, X1
Zhou, G1
Toma, C1
Khandhar, S1
Zalewski, AM1
D'Auria, SJ1
Tu, TM1
Jaber, WA1
Cho, J2
Suwandaratne, NS1
Razek, S1
Choi, YH1
Piper, LFJ1
Watson, DF1
Banerjee, S1
Xie, S1
Lindsay, AP1
Bates, FS1
Lodge, TP1
Hao, Y1
Chapovetsky, A1
Liu, JJ1
Welborn, M1
Luna, JM1
Do, T1
Haiges, R1
Miller Iii, TF1
Marinescu, SC1
Lopez, SA1
Compter, I1
Eekers, DBP1
Hoeben, A1
Rouschop, KMA1
Reymen, B1
Ackermans, L1
Beckervordersantforth, J1
Bauer, NJC1
Anten, MM1
Wesseling, P1
Postma, AA1
De Ruysscher, D1
Lambin, P1
Qiang, L1
Yang, S1
Cui, YH1
He, YY1
Kumar, SK1
Jacobus, SJ1
Cohen, AD1
Weiss, M1
Callander, N1
Singh, AK1
Parker, TL1
Menter, A1
Parsons, B1
Kumar, P1
Kapoor, P1
Rosenberg, A1
Zonder, JA1
Faber, E1
Lonial, S1
Anderson, KC1
Richardson, PG1
Orlowski, RZ1
Wagner, LI1
Rajkumar, SV1
Li, G1
Hou, G1
Cui, J1
Xie, H1
Sun, Z1
Fang, Z1
Dunstand-Guzmán, E1
Hallal-Calleros, C1
Hernández-Velázquez, VM1
Canales-Vargas, EJ1
Domínguez-Roldan, R1
Pedernera, M1
Peña-Chora, G1
Flores-Pérez, I1
Kim, MJ1
Han, C1
White, K1
Park, HJ1
Ding, D1
Boyd, K1
Rothenberger, C1
Bose, U1
Carmichael, P1
Linser, PJ1
Tanokura, M1
Salvi, R1
Someya, S1
Samuni, A1
Goldstein, S1
Divya, KP1
Dharuman, V1
Feng, J2
Qian, Y1
Cheng, Q1
Ma, H1
Ren, X1
Wei, Q1
Pan, W1
Guo, J1
Situ, B1
An, T1
Zheng, L1
Augusto, S1
Ratola, N1
Tarín-Carrasco, P1
Jiménez-Guerrero, P1
Turco, M1
Schuhmacher, M1
Costa, S1
Teixeira, JP1
Costa, C1
Syed, A1
Marraiki, N1
Al-Rashed, S1
Elgorban, AM1
Yassin, MT1
Chankhanittha, T1
Nanan, S1
Sorokina, KN1
Samoylova, YV1
Gromov, NV1
Ogorodnikova, OL1
Parmon, VN1
Ye, J1
Liao, W1
Zhang, P1
Nabi, M1
Cai, Y1
Li, F1
Alsbou, EM1
Omari, KW1
Adeosun, WA1
Asiri, AM1
Marwani, HM1
Barral, M1
Jemal-Turki, A1
Beuvon, F1
Soyer, P1
Camparo, P1
Cornud, F1
Atwater, BD1
Jones, WS1
Loring, Z1
Friedman, DJ1
Namburath, M1
Papirio, S1
Moscariello, C1
Di Costanzo, N1
Pirozzi, F1
Alappat, BJ1
Sreekrishnan, TR1
Volpin, F1
Woo, YC1
Kim, H1
Freguia, S1
Jeong, N1
Choi, JS1
Phuntsho, S1
Shon, HK1
Domínguez-Zambrano, E1
Pedraza-Chaverri, J1
López-Santos, AL1
Medina-Campos, ON1
Cruz-Rivera, C1
Bueno-Hernández, F1
Espinosa-Cuevas, A1
Bulavaitė, A1
Dalgediene, I1
Michailoviene, V1
Pleckaityte, M1
Sauerbier, P1
Köhler, R1
Renner, G1
Militz, H1
Yang, F1
Zhou, Y1
Yu, H2
Yang, J1
Ahmad, N1
Meng, X1
Zhao, R1
Zhuang, J1
Sun, M1
Albayrak, G1
Konac, E1
Dere, UA1
Emmez, H1
Porper, K1
Shpatz, Y1
Plotkin, L1
Pechthold, RG1
Talianski, A1
Champ, CE1
Furman, O1
Shimoni-Sebag, A1
Symon, Z1
Amit, U1
Hemi, R1
Kanety, H1
Mardor, Y1
Cohen, ZR1
Jan, E1
Genssin, H1
Anikster, Y1
Zach, L1
Lawrence, YR1
Caja, L1
Dadras, MS1
Mezheyeuski, A1
Rodrigues-Junior, DM1
Liu, S1
Webb, AT1
Gomez-Puerto, MC1
Ten Dijke, P1
Heldin, CH1
Moustakas, A1
Ward, NP1
Poff, AM1
Koutnik, AP1
D'Agostino, DP1
Lee, JE2
Lim, JH1
Hong, YK1
Yang, SH3
Al Hassan, M1
Fakhoury, I1
El Masri, Z1
Ghazale, N1
Dennaoui, R1
El Atat, O1
Kanaan, A1
El-Sibai, M1
Luber, C1
Gerken, M2
Schaertl, J1
Meier, CR1
Bogdahn, U2
Leitzmann, MF2
Klinkhammer-Schalke, M1
Gerthofer, V1
Oefner, P1
Savage, N1
Prokhorova, IV1
Pyaskovskaya, ON1
Kolesnik, DL1
Solyanik, GI1
Maraka, S1
Groves, MD1
Mammoser, AG1
Melguizo-Gavilanes, I1
Conrad, CA1
Tremont-Lukats, IW1
Loghin, ME1
O'Brien, BJ1
Puduvalli, VK1
Sulman, EP1
Hess, KR1
Aldape, KD1
Gilbert, MR1
de Groot, JF1
Alfred Yung, WK1
Penas-Prado, M1
Lu, VM1
Genbrugge, E1
Gorlia, T1
Chinot, O1
Stupp, R1
Nabors, B1
Weller, M1
Gao, LB1
Tian, S1
Gao, HH1
Xu, YY1
Chhipa, RR1
Pooya, S1
Wortman, M1
Yachyshin, S1
Chow, LM1
Kumar, A1
Quinn, B1
McPherson, C1
Warnick, RE1
Kendler, A1
Giri, S1
Poels, J1
Norga, K1
Viollet, B1
Grabowski, GA1
Dasgupta, B1
Welch, MR1
Grommes, C1
Sesen, J1
Dahan, P1
Scotland, SJ1
Saland, E1
Dang, VT1
Lemarié, A1
Tyler, BM1
Brem, H1
Toulas, C1
Cohen-Jonathan Moyal, E1
Sarry, JE1
Skuli, N1
Cuyàs, E1
Fernández-Arroyo, S1
Corominas-Faja, B1
Rodríguez-Gallego, E1
Bosch-Barrera, J1
Martin-Castillo, B1
De Llorens, R1
Joven, J1
Menendez, JA1
Jun, KH1
Kim, SH2
Jung, JH1
Choi, HJ1
Kim, YI1
Chin, HM1
Adeberg, S1
Bernhardt, D1
Ben Harrabi, S1
Bostel, T1
Mohr, A1
Koelsche, C1
Diehl, C1
Rieken, S1
Debus, J1
Yu, Z1
Zhao, G1
Xie, G1
Zhao, L1
Zhang, Z1
Elmaci, İ1
Altinoz, MA1
Kim, EH1
Lee, JH1
Oh, Y1
Koh, I1
Shim, JK1
Park, J1
Choi, J1
Yun, M1
Jeon, JY1
Huh, YM1
Kim, KS1
Cheong, JH1
Kim, P1
Kang, SG1
Lu, G1
Xue, H1
Kim, DH1
Zhu, JJ1
Kast, RE1
Karpel-Massler, G1
Halatsch, ME1
Sato, A1
Sunayama, J1
Okada, M1
Watanabe, E1
Seino, S1
Shibuya, K1
Suzuki, K1
Narita, Y1
Shibui, S1
Kayama, T1
Kitanaka, C1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients[NCT05298670]Phase 280 participants (Anticipated)Interventional2022-02-01Recruiting
Placebo Controlled Double Blind Crossover Trial of Metformin for Brain Repair in Children With Cranial-Spinal Radiation for Medulloblastoma[NCT02040376]Phase 324 participants (Actual)Interventional2014-06-13Completed
Metformin and Neo-adjuvant Temozolomide and Hypofractionated Accelerated Limited-margin Radiotherapy Followed by Adjuvant Temozolomide in Patients With Glioblastoma Multiforme (M-HARTT STUDY)[NCT02780024]Phase 250 participants (Anticipated)Interventional2015-03-31Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

4 reviews available for metformin and Brain Neoplasms

ArticleYear
The Potential Therapeutic Impact of Metformin in Glioblastoma Multiforme.
    Current medicinal chemistry, 2023, Volume: 30, Issue:7

    Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Diabetes Mellitus, Type 2; Glioblast

2023
An evolving paradigm of cancer stem cell hierarchies: therapeutic implications.
    Theranostics, 2020, Volume: 10, Issue:7

    Topics: Aldehyde Dehydrogenase 1 Family; Animals; Antigens, CD; Antineoplastic Agents; Biomarkers, Tumor; Br

2020
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
A Metabolic Inhibitory Cocktail for Grave Cancers: Metformin, Pioglitazone and Lithium Combination in Treatment of Pancreatic Cancer and Glioblastoma Multiforme.
    Biochemical genetics, 2016, Volume: 54, Issue:5

    Topics: Brain Neoplasms; Cell Proliferation; Drug Therapy, Combination; Gene Expression Regulation, Neoplast

2016

Trials

4 trials available for metformin and Brain Neoplasms

ArticleYear
Assessment of cognitive and neural recovery in survivors of pediatric brain tumors in a pilot clinical trial using metformin.
    Nature medicine, 2020, Volume: 26, Issue:8

    Topics: Adolescent; Adult; Brain; Brain Neoplasms; Cancer Survivors; Child; Child, Preschool; Cognition; Cog

2020
Assessment of cognitive and neural recovery in survivors of pediatric brain tumors in a pilot clinical trial using metformin.
    Nature medicine, 2020, Volume: 26, Issue:8

    Topics: Adolescent; Adult; Brain; Brain Neoplasms; Cancer Survivors; Child; Child, Preschool; Cognition; Cog

2020
Assessment of cognitive and neural recovery in survivors of pediatric brain tumors in a pilot clinical trial using metformin.
    Nature medicine, 2020, Volume: 26, Issue:8

    Topics: Adolescent; Adult; Brain; Brain Neoplasms; Cancer Survivors; Child; Child, Preschool; Cognition; Cog

2020
Assessment of cognitive and neural recovery in survivors of pediatric brain tumors in a pilot clinical trial using metformin.
    Nature medicine, 2020, Volume: 26, Issue:8

    Topics: Adolescent; Adult; Brain; Brain Neoplasms; Cancer Survivors; Child; Child, Preschool; Cognition; Cog

2020
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
A Phase I clinical trial of dose-escalated metabolic therapy combined with concomitant radiation therapy in high-grade glioma.
    Journal of neuro-oncology, 2021, Volume: 153, Issue:3

    Topics: Brain Neoplasms; Combined Modality Therapy; Glioma; Humans; Ketones; Metformin; Middle Aged; Neoplas

2021
Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma.
    Cancer, 2019, 02-01, Volume: 125, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant

2019

Other Studies

35 other studies available for metformin and Brain Neoplasms

ArticleYear
Metformin Is Associated with a Lower Incidence of Benign Brain Tumors: A Retrospective Cohort Study in Patients with Type 2 Diabetes Mellitus.
    Biomolecules, 2021, 09-25, Volume: 11, Issue:10

    Topics: Aged; Brain Neoplasms; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agent

2021
Exploring the Mechanism of Adjuvant Treatment of Glioblastoma Using Temozolomide and Metformin.
    International journal of molecular sciences, 2022, Jul-25, Volume: 23, Issue:15

    Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Diabetes Mellitus, Type 2; DNA

2022
Bacteria-mediated metformin-loaded peptide hydrogel reprograms the tumor immune microenvironment in glioblastoma.
    Biomaterials, 2022, Volume: 288

    Topics: Bacteria; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Hydrogels; Metformin; Peptides; T

2022
Metabolic Heterogeneity of Brain Tumor Cells of Proneural and Mesenchymal Origin.
    International journal of molecular sciences, 2022, Oct-01, Volume: 23, Issue:19

    Topics: Brain; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glucose; Humans; Metformin; Neoplastic Stem

2022
Heterogeneity of Amino Acid Profiles of Proneural and Mesenchymal Brain-Tumor Initiating Cells.
    International journal of molecular sciences, 2023, Feb-06, Volume: 24, Issue:4

    Topics: Amino Acids; Brain; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Glioblastoma; Humans; Met

2023
Metformin use is associated with longer survival in glioblastoma patients with MGMT gene silencing.
    Journal of neuro-oncology, 2023, Volume: 165, Issue:1

    Topics: Brain Neoplasms; Diabetes Mellitus, Type 2; DNA Methylation; DNA Modification Methylases; DNA Repair

2023
Treating cancer therapy-related cognitive impairment.
    Nature medicine, 2020, Volume: 26, Issue:8

    Topics: Brain Neoplasms; Child; Cognitive Dysfunction; Female; Humans; Male; Metformin; Neurons; Radiotherap

2020
Inhibition of mitochondria NADH-Ubiquinone oxidoreductase (complex I) sensitizes the radioresistant glioma U87MG cells to radiation.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020, Volume: 129

    Topics: Brain Neoplasms; Cell Line, Tumor; Electron Transport Complex I; Enzyme Inhibitors; Glioma; Humans;

2020
Combination of metformin and cold atmospheric plasma induces glioma cell death to associate with c-Fos.
    Neoplasma, 2021, Volume: 68, Issue:1

    Topics: Apoptosis; Brain Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferation; Glioma; Humans; Hydrog

2021
Targeting Cancer Cell Metabolism with Metformin, Dichloroacetate and Memantine in Glioblastoma (GBM).
    Turkish neurosurgery, 2021, Volume: 31, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dichloroacetic A

2021
The protein kinase LKB1 promotes self-renewal and blocks invasiveness in glioblastoma.
    Journal of cellular physiology, 2022, Volume: 237, Issue:1

    Topics: AMP-Activated Protein Kinase Kinases; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation

2022
Metformin and Risk of Malignant Brain Tumors in Patients with Type 2 Diabetes Mellitus.
    Biomolecules, 2021, 08-17, Volume: 11, Issue:8

    Topics: Aged; Brain Neoplasms; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Incidence; Male; M

2021
Complex I inhibition augments dichloroacetate cytotoxicity through enhancing oxidative stress in VM-M3 glioblastoma cells.
    PloS one, 2017, Volume: 12, Issue:6

    Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Ce

2017
High-Dose Metformin Plus Temozolomide Shows Increased Anti-tumor Effects in Glioblastoma In Vitro and In Vivo Compared with Monotherapy.
    Cancer research and treatment, 2018, Volume: 50, Issue:4

    Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neopla

2018
Metformin Treatment Inhibits Motility and Invasion of Glioblastoma Cancer Cells.
    Analytical cellular pathology (Amsterdam), 2018, Volume: 2018

    Topics: Antineoplastic Agents; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Pro

2018
Use of metformin and survival of patients with high-grade glioma.
    International journal of cancer, 2019, 01-15, Volume: 144, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Disease-Free Survival; Female; Germany; Glioma; Hum

2019
Combined Modulation of Tumor Metabolism by Metformin and Diclofenac in Glioma.
    International journal of molecular sciences, 2018, Aug-31, Volume: 19, Issue:9

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Prol

2018
Searching for the roots of brain cancer.
    Nature, 2018, Volume: 561, Issue:7724

    Topics: Animals; Brain Neoplasms; Cell Phone; Chickenpox; Chickenpox Vaccine; Developed Countries; Diabetes

2018
Influence of metformin, sodium dichloroacetate and their combination on the hematological and biochemical blood parameters of rats with gliomas C6.
    Experimental oncology, 2018, Volume: 40, Issue:3

    Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dichloroacetic Acid; Female;

2018
Connecting the dots between metformin and high-grade glioma.
    International journal of cancer, 2019, 04-01, Volume: 144, Issue:7

    Topics: Brain Neoplasms; Glioma; Humans; Metformin

2019
Reply to Lu: Connecting the dots between metformin and high-grade glioma.
    International journal of cancer, 2019, 04-01, Volume: 144, Issue:7

    Topics: Brain Neoplasms; Glioma; Humans; Metformin

2019
Use of metformin and outcome of patients with newly diagnosed glioblastoma: Pooled analysis.
    International journal of cancer, 2020, 02-01, Volume: 146, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combin

2020
Metformin inhibits glioma cell U251 invasion by downregulation of fibulin-3.
    Neuroreport, 2013, Jul-10, Volume: 24, Issue:10

    Topics: Actins; Blotting, Western; Brain Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Sur

2013
Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK.
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Jan-28, Volume: 111, Issue:4

    Topics: AMP-Activated Protein Kinase Kinases; Animals; Brain Neoplasms; Cell Cycle; Cell Proliferation; Cell

2014
Retrospective analysis of the effects of steroid therapy and antidiabetic medication on survival in diabetic glioblastoma patients.
    CNS oncology, 2013, Volume: 2, Issue:3

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Cohort Studies;

2013
Metformin inhibits growth of human glioblastoma cells and enhances therapeutic response.
    PloS one, 2015, Volume: 10, Issue:4

    Topics: Adenylate Kinase; Animals; Apoptosis; Autophagy; Brain Neoplasms; Cell Division; Cell Line, Tumor; D

2015
Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype.
    Oncotarget, 2015, May-20, Volume: 6, Issue:14

    Topics: Brain Neoplasms; Cell Line, Tumor; Humans; Isocitrate Dehydrogenase; Metformin; Mutant Proteins; Mut

2015
Clinicopathological significance of N-cadherin and VEGF in advanced gastric cancer brain metastasis and the effects of metformin in preclinical models.
    Oncology reports, 2015, Volume: 34, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Animals; Antigens, CD; Brain Neoplasms; Cadherins; Case-Control Stud

2015
Metformin influences progression in diabetic glioblastoma patients.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2015, Volume: 191, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Blood Glucose; Brain;

2015
Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo.
    Oncotarget, 2015, Oct-20, Volume: 6, Issue:32

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Differentiation; Cell

2015
Inhibition of glioblastoma tumorspheres by combined treatment with 2-deoxyglucose and metformin.
    Neuro-oncology, 2017, 02-01, Volume: 19, Issue:2

    Topics: Animals; Antimetabolites; Apoptosis; Brain Neoplasms; Cell Proliferation; Deoxyglucose; Drug Synergi

2017
Metformin treatment reduces temozolomide resistance of glioblastoma cells.
    Oncotarget, 2016, Nov-29, Volume: 7, Issue:48

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Mov

2016
Stattic and metformin inhibit brain tumor initiating cells by reducing STAT3-phosphorylation.
    Oncotarget, 2017, Jan-31, Volume: 8, Issue:5

    Topics: Adult; Aged; AMP-Activated Protein Kinases; Animals; Antineoplastic Combined Chemotherapy Protocols;

2017
Can the therapeutic effects of temozolomide be potentiated by stimulating AMP-activated protein kinase with olanzepine and metformin?
    British journal of pharmacology, 2011, Volume: 164, Issue:5

    Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Benzodiazepine

2011
Glioma-initiating cell elimination by metformin activation of FOXO3 via AMPK.
    Stem cells translational medicine, 2012, Volume: 1, Issue:11

    Topics: AMP-Activated Protein Kinases; Animals; Blood-Brain Barrier; Brain Neoplasms; Cell Differentiation;

2012